Translational validation of shotgun proteomics findings in cerebrospinal fluid of sporadic cerebral amyloid angiopathy patients
Vervuurt, M.; de Kort, A. M.; Kersten, I.; Rens, A. v.; Klijn, C. J. M.; Schreuder, F. H. B. M.; Lefeber, D.; Kuiperij, H. B.; Verbeek, M. M.
Show abstract
BackgroundPrior research conducted in model rats of CAA Type 1 (rTg-DI) identified a range of cerebrospinal fluid biomarker candidates associated with sCAA pathology. This list of potential biomarkers includes the lysosomal proteases cathepsins B and S (CTSB/CTSS) and hexosaminidase B (HEXB). It is yet unknown if these findings obtained in rTg-DI rats translate to differential protein levels and/or enzyme activities in cerebrospinal fluid (CSF) of sCAA patients. In this study, we attempted to validate CTSB, CTSS and HEXB in CSF as potential biomarkers for sCAA in a human population. Materials and methodsWe have included sCAA patients (n = 34) and control participants (n = 27) from our BIONIC/CAFE cohort. We analysed the CSF of these participants with ELISA for protein levels of CTSB and CTSS. Additionally, we used in-house enzyme assays to determine activity levels of total hexosaminidase and hexosaminidase A (HEXA) in CSF. The proportion of HEXA activity to total HEX activity was used as a proxy for HEXB activity. ResultsCSF CTSB and CTSS protein levels were not significantly different between sCAA and controls (p = 0.21 and p = 0.34). Total HEX activity was unaltered as well (p = 0.11), whereas a significant decrease was observed in HEXA activity levels (p = 0.05). HEXA / total HEX activity levels (as a proxy for HEXB activity) were unaltered between sCAA patients and controls (p = 0.19). Additionally, CTSB and CTSS protein levels positively associated with total HEX activity (rsp = 0.37, p = 0.005; rsp = 0.40, p = 0.003). ConclusionThe contrasting results between biomarker discovery in rats and validation in human participants highlight the challenges and complexities of biomarker research. These findings offer valuable insights into the nuances of disease and the difficulties in translating laboratory findings using animal models to clinical practice. Understanding these discrepancies is essential for improving the precision of biomarker translation, ensuring clinical relevance, and developing comprehensive biomarker panels for CAA and related conditions.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Post-translational modifications glycosylation and phosphorylation of the major hepatic plasma protein fetuin-A are associated with severity of CNS inflammation in children 95%
- Differences in splicing defects between the grey and white matter in myotonic dystrophy type 1 92%
- Protective mutation A673T as a potential gene therapy for most forms of APP Familial Alzheimer's Disease 92%
Similar papers in this journal
- Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays. 93%
- Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays 91%
- Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers 90%
Similar papers in this journal
Similar papers in this journal
- Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay 92%
- Immunomodulatory Therapy with Glatiramer Acetate Reduces Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Experimental Autoimmune Encephalomyelitis 91%
- Correlates of patient-reported cognitive performance with regard to disability 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.